التفاصيل البيبلوغرافية
| العنوان: |
Is Distal Chronic Thromboembolic Pulmonary Hypertension Treatable with PAH Targeted Drugs? |
| المؤلفون: |
Cannon, J. E., Pepke-Zaba, J. |
| المصدر: |
Seminars in Respiratory & Critical Care Medicine; Oct2013, Vol. 34 Issue 5, p620-626, 7p |
| مصطلحات موضوعية: |
PULMONARY hypertension, THERAPEUTICS, ENDARTERECTOMY, PROSTANOIDS, HEALTH of patients, ETIOLOGY of diseases |
| مستخلص: |
Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening condition that historically has a poor outcome with supportivemedical treatment. Pulmonary endarterectomy (PEA) is the treatment of choice and offers the only chance of cure. A significant proportion of patients is either not suitable due to the distal distribution of the disease or has persistent pulmonary hypertension (PH) after PEA. Despite the lack of licensed therapies for CTEPH, the similarities in pathobiology of pulmonary arterial hypertension (PAH) and CTEPH has led to the compassionate use of PAH therapies in CTEPH patients. This article reviews the pathobiology of CTEPH and summaries the available evidence for the use of PAH-targeted drugs in CTEPH. [ABSTRACT FROM AUTHOR] |
|
Copyright of Seminars in Respiratory & Critical Care Medicine is the property of Thieme Medical Publishing Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
